Notification
No new Notification messages
Enviro Infra Engineers IPO is Open!
Apply for the Enviro Infra Engineers IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Torrent Pharma Q2 Results FY24-25 Highlights: Cons Revenue ₹2,889 Cr Up 9%, PAT ₹453 Cr Up 17%

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Torrent Pharmaceuticals reported consolidated revenue of ₹2,889 crore and a PAT of ₹453 crore for Q2 FY24-25, representing a growth of 17% in profit. Detailed insights into segment-wise performances and management commentary are provided below.

Torrent Pharmaceuticals Limited posted its consolidated financial results for Q2 FY24-25, showcasing robust growth. The company reported consolidated revenue of ₹2,889 crore and Profit After Tax (PAT) of ₹453 crore, reflecting a year-on-year growth of 17%.

Key Highlights

  • Revenue Growth: Total revenue stood at ₹2,889 crore, up 9% from the previous year’s figure of ₹2,660 crore.
  • Net Profit: Torrent Pharma achieved ₹453 crore in PAT, marking a 17% increase compared to ₹386 crore in Q2 FY23-24.
  • EBITDA Performance: The operating EBITDA stood at ₹939 crore, representing a 14% increase year-on-year.
  • Margins: The company reported an operating EBITDA margin of 32.5%, with a gross margin of 76.5%.

TORRENT PHARMACEUTICALS L

Trade

3167.165.15 (2.10 %)

Updated - 22 November 2024
3189.70day high
DAY HIGH
3102.05day low
DAY LOW
290862
VOLUME (BSE)

Quarterly - Torrent Pharma Q2 Results FY24-25

Torrent Pharma’s quarterly performance shows consistent growth across various metrics, driven by strong market traction in branded markets. Here are some key highlights.

Metric

Q2 FY24-25

Q2 FY23-24

% Change

Revenue from Operations

₹2,889 Cr

₹2,660 Cr

9%

Profit After Tax (PAT)

₹453 Cr

₹386 Cr

17%

EBITDA

₹939 Cr

₹825 Cr

14%

EBITDA Margin

32.50%

31%

1.50%

Gross Margin

76.50%

75%

1.50%

R&D Spend

₹145 Cr

₹132 Cr

10%

Segment Highlights

  • India Business: The India segment led growth with revenues of ₹1,632 crore, up by 13%, primarily due to outperformance in chronic therapies.
  • Brazil Market: Brazil revenues grew by 4%, with constant currency revenues showing a robust 17% increase.
  • Germany: The German business recorded ₹288 crore in revenues, representing an 8% increase. The company continues to win incremental tenders in this market.
  • US Market: Revenue from the US was ₹268 crore, up by 8%. Adjusted for one-off income in H1 FY23-24, there was a marginal decrease of 2%.

Sector Expectations for Torrent Pharma Q2 Results FY24-25

Torrent Pharma's performance are at par with sector expectations, with its strong presence in chronic therapies driving consistent growth in key markets such as India, Brazil, and Germany. The pharmaceutical sector anticipates continued recovery, and Torrent Pharma is well-positioned to capitalize on this momentum.

Management Commentary

Torrent Pharma's management highlighted the company's strong Q2 performance, attributing it to continued traction in branded markets and operational efficiencies. They remain confident in achieving their year-end targets despite the scheduled maintenance shutdown in the insulin segment, which will see recovery in Q4 FY25.

Check out Torrent Pharma's past performances in previous quarters and financial years.

Conclusion

Torrent Pharma’s Q2 FY24-25 results demonstrate consistent growth across all key markets, with a revenue of ₹2,889 crore and PAT of ₹453 crore, a 17% increase year-on-year. With its strong focus on branded markets and operational efficiencies, the company remains on track to achieve its growth targets for the year.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text